

**Appendix 3 Supplemental Table Study group comparison of admission clinical characteristics and respiratory/circulatory support use during admission**

Clinical characteristics	Time periods and designated study groups			P values	
	Nov 2019-Feb 2020	Mar 2020 – Aug 2020 (Wave 1)			
	Pre-COVID Group N=170 (%)	COVID-ve Group N=170 (%)	COVID+ve Group N=85 (%)		
<b>Comorbidities at admission</b>					
<b>COPD</b>	43 (25.3)	49 (28.8)	17 (20.0)	0.312	
<b>Asthma</b>	7 (4.1)	9 (5.3)	3 (3.5)	0.780	
<b>Heart Failure</b>	40 (23.5)	48 (28.2)	16 (18.8)	0.240	
<b>Hypertension</b>	95 (55.9)	104 (61.2)	57 (67.1)	0.217	
<b>Atrial fibrillation</b>	<b>45 (26.5)</b>	<b>55 (32.4)</b>	<b>13 (15.3)</b>	<b>0.015</b>	
<b>Coronary artery disease</b>	52 (30.6)	52 (30.6)	22 (25.9)	0.697	
<b>Chronic liver disease</b>	3 (1.8)	11 (6.5)	3 (3.5)	0.084	
<b>Diabetes mellitus</b>	48 (28.2)	56 (32.9)	26 (30.6)	0.642	
<b>Chronic kidney disease</b>	32 (18.8)	38 (22.4)	19 (22.4)	0.681	
<b>Obesity</b>	6 (3.5)	15 (8.8)	4 (4.7)	0.102	
<b>HIV infection</b>	0 (0.0)	0 (0.0)	1 (1.2)	0.135	
<b>Dementia</b>	<b>47 (27.7)</b>	<b>44 (25.9)</b>	<b>35 (41.2)</b>	<b>0.032</b>	
<b>Active cancer</b>	44 (25.9)	37 (21.8)	11 (12.9)	0.061	
<b>Other comorbidity</b>	<b>108 (63.5)</b>	<b>102 (60.0)</b>	<b>66 (77.7)</b>	<b>0.018</b>	
<b>Symptoms/signs at admission</b>					
<b>Breathlessness</b>	<b>72 (42.4)</b>	<b>80 (47.1)</b>	<b>54 (63.5)</b>	<b>0.006</b>	
<b>Airway secretions</b>	28 (16.5)	16 (9.4)	7 (8.2)	0.066	
<b>Cough</b>	<b>46 (27.1)</b>	<b>33 (19.4)</b>	<b>34 (40.0)</b>	<b>0.002</b>	
<b>Agitation</b>	11 (6.5)	14 (8.2)	10 (11.8)	0.350	
<b>Drowsiness</b>	68 (40.0)	57 (33.5)	39 (45.9)	0.143	
<b>Pain</b>	<b>50 (29.4)</b>	<b>49 (28.8)</b>	<b>9 (10.6)</b>	<b>0.002</b>	
<b>Cognitive impairment</b>	57 (33.5)	59 (34.7)	35 (41.2)	0.465	
<b>Fatigue</b>	88 (51.8)	83 (48.8)	51 (60.0)	0.239	
<b>Fever</b>	<b>16 (9.4)</b>	<b>23 (13.5)</b>	<b>46 (54.1)</b>	<b>&lt;0.001</b>	
<b>Other symptoms</b>	90 (52.9)	79 (46.5)	42 (49.4)	0.490	

<b>Respiratory/circulatory support used during admission</b>				
<b>BIPAP</b>	22 (12.9)	17 (10.0)	4 (4.7)	0.121
<b>High flow nasal cannula</b>	<b>63 (37.1)</b>	<b>49 (28.8)</b>	<b>46 (54.1)</b>	<b>&lt;0.001</b>
<b>Intubated</b>	45 (26.5)	43 (25.3)	14 (16.5)	0.186
<b>Other respiratory support</b>	50 (29.4)	52 (30.6)	31 (36.5)	0.502
<b>Vasopressor use</b>	43 (25.3)	47 (27.7)	13 (15.3)	0.087